{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:44:07Z","timestamp":1792813447747,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-18336-9","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T13:34:06Z","timestamp":1758807246000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["A nomogram using transition zone PSA density for detecting clinically significant prostate cancer in PI-RADS 3 lesions"],"prefix":"10.1038","volume":"15","author":[{"given":"Cheng","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borui","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,25]]},"reference":[{"key":"18336_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"18336_CR2","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/S0140-6736(21)00950-8","volume":"398","author":"S Sandhu","year":"2021","unstructured":"Sandhu, S. et al. Prostate cancer. Lancet 398, 1075\u20131090. https:\/\/doi.org\/10.1016\/S0140-6736(21)00950-8 (2021).","journal-title":"Lancet"},{"key":"18336_CR3","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1007\/s00330-011-2377-y","volume":"22","author":"JO Barentsz","year":"2012","unstructured":"Barentsz, J. O. et al. ESUR prostate MR guidelines 2012. Eur. Radiol. 22, 746\u2013757. https:\/\/doi.org\/10.1007\/s00330-011-2377-y (2012).","journal-title":"Eur. Radiol."},{"key":"18336_CR4","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.eururo.2015.08.052","volume":"69","author":"JC Weinreb","year":"2016","unstructured":"Weinreb, J. C. et al. PI-RADS prostate Imaging \u2013 Reporting and data system: 2015, version 2. Eur. Urol. 69, 16\u201340 (2016).","journal-title":"Eur. Urol."},{"key":"18336_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.02.033","author":"B Turkbey","year":"2019","unstructured":"Turkbey, B. et al. Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2. Eur. Urol. ;76:340\u2013351. https:\/\/doi.org\/10.1016\/j.eururo.2019.02.033. (2019)."},{"key":"18336_CR6","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.euf.2019.06.014","volume":"6","author":"M Maggi","year":"2020","unstructured":"Maggi, M. et al. Prostate imaging reporting and data system 3 category cases at multiparametric magnetic resonance for prostate cancer: A systematic review and Meta-analysis. Eur. Urol. Focus. 6, 463\u2013478. https:\/\/doi.org\/10.1016\/j.euf.2019.06.014 (2020).","journal-title":"Eur. Urol. Focus"},{"key":"18336_CR7","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1111\/bju.13465","volume":"119","author":"S Washino","year":"2017","unstructured":"Washino, S. et al. Combination of prostate imaging reporting and data system (PI-RADS) score and prostate-specific antigen (PSA) density predicts biopsy outcome in prostate biopsy Na\u00efve patients. BJU Int. 119, 225\u2013233. https:\/\/doi.org\/10.1111\/bju.13465 (2017).","journal-title":"BJU Int."},{"key":"18336_CR8","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.euf.2019.11.012","volume":"7","author":"M G\u00f6rtz","year":"2021","unstructured":"G\u00f6rtz, M. et al. The value of prostate-specific antigen density for prostate Imaging-Reporting and data system 3 lesions on multiparametric magnetic resonance imaging: A strategy to avoid unnecessary prostate biopsies. Eur. Urol. Focus. 7, 325\u2013331. https:\/\/doi.org\/10.1016\/j.euf.2019.11.012 (2021).","journal-title":"Eur. Urol. Focus"},{"key":"18336_CR9","doi-asserted-by":"publisher","unstructured":"Stevens, E. et al. Clinical utility of PSAD combined with PI-RADS category for the detection of clinically significant prostate cancer. Urol. Oncol. 38 https:\/\/doi.org\/10.1016\/j.urolonc.2020.05.024 (2020). :846.e9-846.e16.","DOI":"10.1016\/j.urolonc.2020.05.024"},{"key":"18336_CR10","doi-asserted-by":"publisher","unstructured":"Wang, S. et al. Diagnostic performance of prostate-specific antigen density for detecting clinically significant prostate cancer in the era of magnetic resonance imaging: A systematic review and Meta-analysis. Eur. Urol. Oncol. S2588-9311 (23)00165-7). https:\/\/doi.org\/10.1016\/j.euo.2023.08.002 (2023).","DOI":"10.1016\/j.euo.2023.08.002"},{"key":"18336_CR11","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/0090-4295(94)90170-8","volume":"43","author":"J Kalish","year":"1994","unstructured":"Kalish, J., Cooner, W. H. & Graham, S. D. Serum PSA adjusted for volume of transition zone (PSAT) is more accurate than PSA adjusted for total gland volume (PSAD) in detecting adenocarcinoma of the prostate. Urology 43, 601\u2013606. https:\/\/doi.org\/10.1016\/0090-4295(94)90170-8 (1994).","journal-title":"Urology"},{"key":"18336_CR12","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s12894-020-00717-z","volume":"20","author":"T-H Chang","year":"2020","unstructured":"Chang, T-H. et al. Zonal adjusted PSA density improves prostate cancer detection rates compared with PSA in Taiwanese males with PSA\u2009<\u200920 ng\/ml. BMC Urol. 20, 151. https:\/\/doi.org\/10.1186\/s12894-020-00717-z (2020).","journal-title":"BMC Urol."},{"key":"18336_CR13","doi-asserted-by":"publisher","first-page":"615","DOI":"10.7863\/jum.2004.23.5.615","volume":"23","author":"DJ Sung","year":"2004","unstructured":"Sung, D. J. et al. Comparison of prostate-specific antigen adjusted for transition zone volume versus prostate-specific antigen density in predicting prostate cancer by transrectal ultrasonography. J. Ultrasound Med. Off J. Am. Inst. Ultrasound Med. 23, 615\u2013622. https:\/\/doi.org\/10.7863\/jum.2004.23.5.615 (2004).","journal-title":"J. Ultrasound Med. Off J. Am. Inst. Ultrasound Med."},{"key":"18336_CR14","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.urolonc.2011.06.012","volume":"31","author":"P Tang","year":"2013","unstructured":"Tang, P. et al. Transition zone PSA density improves the prostate cancer detection rate both in PSA 4.0\u201310.0 and 10.1\u201320.0 ng\/ml in Chinese men. Urol. Oncol. 31, 744\u2013748. https:\/\/doi.org\/10.1016\/j.urolonc.2011.06.012 (2013).","journal-title":"Urol. Oncol."},{"key":"18336_CR15","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1186\/s12885-023-11306-2","volume":"23","author":"Z Chen","year":"2023","unstructured":"Chen, Z. et al. A novel clinically significant prostate cancer prediction system with multiparametric MRI and PSA: P.Z.A. Score. BMC Cancer. 23, 1138. https:\/\/doi.org\/10.1186\/s12885-023-11306-2 (2023).","journal-title":"BMC Cancer"},{"key":"18336_CR16","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1007\/s00432-017-2389-3","volume":"143","author":"Y Wang","year":"2017","unstructured":"Wang, Y. et al. Prostate transitional zone volume-based nomogram for predicting prostate cancer and high progression prostate cancer in a real-world population. J. Cancer Res. Clin. Oncol. 143, 1157\u20131166. https:\/\/doi.org\/10.1007\/s00432-017-2389-3 (2017).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"18336_CR17","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/S1470-2045(24)00220-1","volume":"25","author":"A Saha","year":"2024","unstructured":"Saha, A. et al. Artificial intelligence and radiologists in prostate cancer detection on MRI (PI-CAI): an international, paired, non-inferiority, confirmatory study. Lancet Oncol. 25, 879\u2013887. https:\/\/doi.org\/10.1016\/S1470-2045(24)00220-1 (2024).","journal-title":"Lancet Oncol."},{"key":"18336_CR18","doi-asserted-by":"publisher","first-page":"null","DOI":"10.1056\/NEJMoa2100852","volume":"0","author":"M Eklund","year":"2021","unstructured":"Eklund, M. et al. MRI-Targeted or standard biopsy in prostate cancer screening. N Engl. J. Med. 0, null. https:\/\/doi.org\/10.1056\/NEJMoa2100852 (2021).","journal-title":"N Engl. J. Med."},{"key":"18336_CR19","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/S1470-2045(21)00348-X","volume":"22","author":"T Nordstr\u00f6m","year":"2021","unstructured":"Nordstr\u00f6m, T. et al. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial. Lancet Oncol. 22, 1240\u20131249. https:\/\/doi.org\/10.1016\/S1470-2045(21)00348-X (2021).","journal-title":"Lancet Oncol."},{"key":"18336_CR20","doi-asserted-by":"publisher","first-page":"108660","DOI":"10.1016\/j.ejrad.2019.108660","volume":"120","author":"AF Schneider","year":"2019","unstructured":"Schneider, A. F. et al. Comparison of PSA-density of the transition zone and whole gland for risk stratification of men with suspected prostate cancer: A retrospective MRI-cohort study. Eur. J. Radiol. 120, 108660. https:\/\/doi.org\/10.1016\/j.ejrad.2019.108660 (2019).","journal-title":"Eur. J. Radiol."},{"key":"18336_CR21","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/S0022-5347(01)62911-2","volume":"160","author":"B Djavan","year":"1998","unstructured":"Djavan, B. et al. Prostate specific antigen density of the transition zone for early detection of prostate cancer. J. Urol. 160, 411\u2013418. https:\/\/doi.org\/10.1016\/S0022-5347(01)62911-2 (1998).","journal-title":"J. Urol."},{"key":"18336_CR22","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-024-10700-z","author":"CA Hamm","year":"2024","unstructured":"Hamm, C. A. et al. Reduction of false positives using zone-specific prostate-specific antigen density for prostate MRI-based biopsy decision strategies. Eur. Radiol. https:\/\/doi.org\/10.1007\/s00330-024-10700-z (2024).","journal-title":"Eur. Radiol."},{"key":"18336_CR23","doi-asserted-by":"publisher","first-page":"126","DOI":"10.4103\/aja202218","volume":"25","author":"C Huang","year":"2023","unstructured":"Huang, C. et al. New model of PIRADS and adjusted prostatespecific antigen density of peripheral zone improves the detection rate of initial prostate biopsy: a diagnostic study. Asian J. Androl. 25, 126. https:\/\/doi.org\/10.4103\/aja202218 (2023).","journal-title":"Asian J. Androl."},{"key":"18336_CR24","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1016\/j.juro.2008.01.033","volume":"179","author":"CS Elliott","year":"2008","unstructured":"Elliott, C. S., Shinghal, R. & Presti, J. C. The performance of prostate specific antigen, prostate specific antigen density and transition zone density in the era of extended biopsy schemes. J. Urol. 179, 1756\u20131761. https:\/\/doi.org\/10.1016\/j.juro.2008.01.033 (2008).","journal-title":"J. Urol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-18336-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-18336-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-18336-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T13:34:06Z","timestamp":1758807246000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-18336-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,25]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["18336"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-18336-9","relation":{"references":[{"id-type":"doi","id":"10.1016\/j.eururo.2019.02.033","asserted-by":"subject"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,25]]},"assertion":[{"value":"16 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was waived by the Institutional Review Board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Patients\u2019 data were anonymized. Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"32830"}}